OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NACompletedINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

April 12, 2023

Study Completion Date

May 10, 2023

Conditions
Opioid-use Disorder
Interventions
DEVICE

OXD01 digital therapy

OXD01 digital therapy, 1-2 times per week 15-30 minutes each time.

OTHER

Standard of Care

Sublingual buprenorphine/naloxone Medication-assisted treatment, the current standard for opioid addiction; the use of medications in combination with counseling

Trial Locations (21)

10466

Dr. Vando Medical Services PC, The Bronx

18704

MD Medical Management, Kingston

19041

Thalia Medical Center, Haverford

19116

Medically Assisted Recovery Service, Philadelphia

19462

Institute of Addiction Medicine, Plymouth Meeting

33024

Humanity Clinical Research, Pembroke Pines

35215

Parkway Medical Center, Birmingham

39232

Precise Research Centers, Flowood

41017

Otrimed Clinical Research, Edgewood

44130

North Star Medical Research, Middleburg Heights

44720

Neuro-Behavioral Clinical Research Center, North Canton

45069

CincyScience, West Chester

45417

Midwest Clinical Research Center, Dayton

48126

Patient First Medical Clinic, Dearborn

62034

Southern Illinois Associates LLC, Glen Carbon

63128

PsychCare Consultants Research, St Louis

73112

Pahl Pharmaceuticals Professions, Oklahoma City

84058

Aspen Clinical Research, Orem

92054

North County Clinical Research, Oceanside

92103

Artemis Institute for Clinical Research, San Diego

92120

Wetlin Research Associates, Inc, San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Orexo AB

INDUSTRY

NCT04948307 - OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder | Biotech Hunter | Biotech Hunter